Figure 1.2. Diagrammatic Presentations of Small Interfering RNA (siRNA) and MicroRNA (miRNA) Action

Figure 1.3. Timeline of Significant Events in the Discovery and Development of RNAi

Figure 1.4. Gene Therapy in Clinical Trials

Figure 2.1. The Normal Macula Compared to Wet and Dry Macular Degeneration

Figure 4.1. Alnylam’s Systemic RNAi Delivery Technology that Is Clinically Relevant

Figure 4.2. RNAi-Mediated Gene Silencing in Mammals Using Short Hairpin RNAs

Figure 4.3. Inhibition of Hepatitis C Virus (HCV) Internal Ribosomal Entry Site-Mediated Reporter Gene Expression in Mice

Figure 5.1. Key Attributes of RNAi Drugs for Use in Humans

Figure 5.2. Possible Risks Before Launching a Successful RNAi Drug

Figure 6.1. RNAi Drugs in Development (Alnylam)

Figure 6.2. RNAi Drugs in Development (CytRx)

Figure 6.3. RNAi Drugs in Development (Intradigm)

Figure 6.4. RNAi Drugs in Development (Sirna)

Table 1.1. Summary of RNAi Results Presented at the 2005 American Society of Gene Therapy Conference, St. Louis, Missouri

Table 4.1. Pros and Cons of Electroporetic Delivery

Table 4.2. Pros and Cons of Viral Delivery

Table 4.3. Pros and Cons of Lipid Delivery

Table 6.1. Companies with Plans of Launching RNAi Drugs for One or More Indications

Table 6.2. RNAi Therapeutics Companies: Patent Profiles